Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Drug Price Negotiation Not A Major Threat To Pharma – Even If It Passes

Executive Summary

Biopharma analysts discuss the likely impact of the drug pricing reform provisions in the Build Back Better legislation, which has hit a roadblock created by Democratic Senator Joe Manchin of West Virginia.

You may also be interested in...



Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform

Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.

Tweaks To CBO Model May Add Another Hurdle To Congressional Drug Pricing Reform Effort

New model suggests extra hit for accelerated approval drugs. But despite Congress and President Biden looking toward a scaled-backed version of the Build Back Better reconciliation package, many health care politics experts believe drug price negotiation will make it into law this year. 

Who Needs Negotiation? US Rx Prices Are Falling – Thanks To Generics

A Congressional Budget Office review of prescription drug pricing trends over the past decade shows a surprising fact: the average costs per prescription in the US is falling. That probably won’t change the political debate over drug prices – but maybe it should.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel